Sanofi S.A. — Ethics Grade C

Sanofi S.A. receives an overall ethics grade of C (52/100) on CancelCo's corporate accountability database. Sector: Pharmaceuticals. Market cap: Large Cap.

Category scores

• labor: 60
• privacy: 70
• consumer: 25
• environment: 65
• humanRights: 55

Documented incidents (3)

• Dengvaxia Vaccine Scandal (high, 2019) — The Philippines government filed criminal charges against Sanofi officials after its dengue vaccine was linked to increased disease severity in some children, resulting in multiple deaths and a public health crisis.
• Depakine Pregnancy Risks (high, 2020) — Sanofi was indicted in France for manslaughter and failing to properly warn pregnant women about the risks of birth defects associated with the epilepsy drug Depakine.
• Insulin Price Fixing Allegations (medium, 2023) — Sanofi, along with other major insulin manufacturers, faced numerous lawsuits and congressional inquiries regarding the artificial inflation of life-saving insulin prices in the US market.

Documented good deeds

• Foundation S Launch — Created a foundation dedicated to improving medicine access for childhood cancer and neglected tropical diseases in low-income countries.

Ethical alternatives

• Novo Nordisk — Industry leader in sustainable production and more transparent pricing strategies for chronic medication.